J

    Janux Therapeutics Inc (JANX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $18.22
    +0.19 (+1.05%)

    Market Cap: $1.10B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    71%(15/21)
    Avg Surprise
    +8.83%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.50
    Range$-0.67 - $-0.04
    13 analysts
    EPS Revisions
    1
    0
    7d
    1
    2
    30d
    EPS Estimate Drift
    90d ago$-0.52-3.5%
    60d ago$-0.52-3.5%
    30d ago$-0.52-3.7%
    7d ago$-0.51-2.3%
    Current$-0.50
    Revenue Consensus
    $6M
    Range$0 - $35M
    13 analysts
    Dec 31, 2026
    EPS Consensus$-0.45
    Range$-0.98 - $0.34
    13 analysts
    Revenue Consensus
    $409790
    Range$-15048210 - $48M
    14 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.45---
    Sep 26EST
    		-$-0.50---
    Jun 26
    		$-0.35$-0.26-34.62%Miss+36.4%
    Mar 26
    		$-0.39$-0.52+25.00%Beat-2.6%
    Dec 25
    		$-0.51$-0.65+21.54%Beat-41.7%
    Sep 25
    		$-0.39$-0.61+36.07%Beat+23.5%
    Jun 25
    		$-0.55$-0.48-14.58%Miss-400.0%
    Mar 25
    		$-0.38$-0.39+2.56%Beat-26.7%
    Dec 24
    		$-0.36$-0.43+15.59%Beat-44.0%
    Sep 24
    		$-0.51$-0.36-41.67%Miss-104.0%
    Jun 24
    		$-0.11N/A+62.07%Beat+73.8%
    Mar 24
    		$-0.30$-0.33+9.09%Beat+28.6%
    Dec 23
    		$-0.25$-0.39+35.90%Beat+35.9%
    Sep 23
    		$-0.25$-0.43+41.86%Beat+37.5%
    Jun 23
    		$-0.42$-0.51+17.65%Beat-2.4%
    Mar 23
    		$-0.42$-0.46+8.70%Beat-31.2%
    Dec 22
    		$-0.39$-0.49+20.41%Beat-18.2%
    Sep 22
    		$-0.40$-0.53+24.53%Beat-53.8%
    Jun 22
    		$-0.41$-0.39-5.13%Miss-173.3%
    Mar 22
    		$-0.32$-0.37+13.51%Beat+84.2%
    Dec 21
    		$-0.33$-0.31-6.45%Miss+87.5%
    Sep 21
    		$-0.26$-0.17-52.94%Miss+88.2%
    Jun 21
    		$-0.15$-0.16+6.25%Beat-
    Mar 21
    		$-2.02$0.00N/AMiss-
    Dec 20
    		$-2.63$0.00N/AMiss-
    Dec 19
    		$-2.20$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-11.11EV/EBITDA-33.80x
    Price/FCF-27.35xFCF Yield-3.66%
    Profitability
    Profit Margin0.00%Operating Margin-308.70%
    ROE-10.70%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio16.35xQuick Ratio16.35x
    Trading Statistics
    Beta2.51Avg Volume705.63K
    52-Week High$35.3452-Week Low$12.12

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$18.04
    SMA 20$17.11
    SMA 50$16.17
    SMA 200$15.76
    EMA 10$17.96
    EMA 20$17.34
    EMA 50$16.35
    EMA 200$17.02

    MACD

    Line: 0.75Signal: 0.63Hist: 0.12

    ADX

    ADX: 27.3+DI: 28.6-DI: 19.6

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down4.0
    PSAR$19.14

    Bollinger Bands

    Upper Band$19.27
    Lower Band$14.95
    %B Position2524%(Upper)
    Band Width0.76

    RSI (14-Day)

    Neutral
    63.1

    Momentum Oscillators

    Stoch %K76.8
    Stoch %D83.2
    Williams %R-26.8
    ROC (10d)12.1%
    Momentum1.96
    CCI (20d)70.5
    MFI (14d)60.0

    Volatility Measures

    ATR (14d)$0.68(3.7%)
    StdDev (20d)1.08
    Hist Vol42.2%(High)

    Volume Flow

    VWAP$18.09
    OBV-30.2M
    AD Line-19.7M
    CMF (20d)0.048

    Volume Metrics

    Avg Vol (20d)713.0K
    Vol Ratio1.0x
    VWMA (20d)$17.26

    Pivot Points

    R3$19.27
    R2$19.00
    R1$18.51
    Pivot Point$18.24
    S1$17.76
    S2$17.49
    S3$17.00

    Advanced Oscillators

    TSI30.95
    Ultimate Osc54.5
    KST132.25

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$10.27M$3.73M$7.88M$10.00M$0$0$-8,512,000$439,000$8.90M$1.25M$2.46M$2.52M
    Cost of Revenue$0$0$8.94M$0$0$0$20.81M$0$0$0$531,000$0
    Gross Profit$10.27M$3.73M$-1,060,000$10.00M$0$0$-20,806,000$439,000$8.90M$1.25M$2.46M$2.52M
    Operating Expenses$41.96M$37.95M$42.40M$45.25M$45.12M$34.90M$29.02M$36.28M$22.72M$21.41M$18.60M$18.33M
    R&D$30.99M$26.81M$31.55M$34.63M$34.66M$25.05M$20.81M$18.61M$14.90M$14.07M$12.24M$11.89M
    SG&A$10.96M$11.13M$10.85M$10.62M$10.45M$9.84M$8.22M$17.67M$7.82M$7.34M$6.36M$6.44M
    Operating Income$-31,690,000$-34,213,000$-42,401,000$-35,251,000$-45,118,000$-34,897,000$-29,022,000$-35,842,000$-13,822,000$-20,161,000$-16,137,000$-15,813,000
    Interest Income$9.72M$9.85M$10.46M$10.94M$11.26M$11.39M$8.81M$7.78M$7.86M$5.40M$4.38M$4.25M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-21,972,000$-24,361,000$-31,946,000$-24,313,000$-33,858,000$-23,508,000$-20,216,000$-28,059,000$-5,959,000$-14,760,000$-11,758,000$-11,568,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-21,972,000$-24,361,000$-31,946,000$-24,313,000$-33,858,000$-23,508,000$-20,216,000$-28,059,000$-5,959,000$-14,760,000$-11,758,000$-11,568,000
    EBITDA$-34,113,000$-36,368,000$-45,457,000$-39,373,000$-49,783,000$-38,599,000$-31,437,000$-38,230,000$-16,289,000$-21,416,000$-17,667,000$-17,421,000
    EBIT$-31,690,000$-34,213,000$-42,401,000$-35,251,000$-45,118,000$-34,897,000$-29,022,000$-35,842,000$-13,822,000$-20,161,000$-16,137,000$-15,813,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about JANX

    News

    Wolfe Research Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $23

    Wolfe Research has initiated coverage on Janux Therapeutics (JANX.US) with a Buy rating. The firm has set a price target of $23 for the company's shares. This initiation suggests a positive outlook from Wolfe Research regarding Janux Therapeutics' future performance.

    Moomoo•8/25/26•
    Bullish

    Wolfe Research upgrades Janux stock rating on autoimmune data

    Wolfe Research upgraded Janux Therapeutics shares from Peerperform to Outperform with a $23 price target, citing upcoming autoimmune data as a key catalyst. The stock has shown volatility and is considered undervalued by InvestingPro. Janux also recently announced the departure of its Chief Medical Officer, William Go, and is actively seeking a replacement.

    Investing.com•8/24/26•
    Bullish

    Is Janux Therapeutics (JANX) Narrowing Losses Enough To Shift Its Long-Term Risk Profile?

    Janux Therapeutics (JANX) reported reduced net losses and lower basic loss per share for Q2 and the first six months of 2026, indicating more efficient cost management. While this eases near-term financing concerns for the pre-profit biotech, its investment narrative still hinges on the success of its TRACTr and ARM platforms, clinical trial data, and the Bristol Myers Squibb partnership. The company faces significant risks related to trial outcomes, cash burn, potential dilution, and a potentially inflated share price compared to its estimated value.

    Sahm•8/21/26•
    Neutral

    JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know

    Janux Therapeutics (JANX) shares have increased by 19.1% over the past three months and 25.3% year-to-date, driven by advancements in its oncology and autoimmune pipelines. Key developments include progress in prostate cancer candidate JANX007 and the launch of autoimmune candidate JANX011. The company also maintains strategic collaborations with Merck & Co. and Bristol Myers Squibb and boasts a strong balance sheet with $970.9 million in cash.

    TradingView•8/21/26•
    Bullish

    Is Janux Therapeutics (JANX) Narrowing Losses Enough To Shift Its Long-Term Risk Profile?

    Janux Therapeutics (JANX) reported reduced net losses of US$21.97 million for Q2 2026 and US$46.33 million for the six-month period, indicating more efficient cost management. While these narrowing losses ease near-term financing concerns, Janux remains a pre-profit, high-spend biotech company heavily reliant on future clinical trial outcomes and its partnership with Bristol Myers Squibb. Investors are advised to consider the company's valuation report, which suggests an inflated share price compared to its estimated value.

    Simply Wall Street•8/20/26•
    Neutral

    Frequently Asked Questions About JANX

    Does JANX pay dividends?
    Janux Therapeutics Inc (JANX) does not currently pay a regular dividend.
    What is JANX's market cap?
    Janux Therapeutics Inc (JANX) has a market capitalization of $1.10B with a current stock price of $18.22.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In